Acute myelogenous leukemia (AML) is the most common leukemia among adults. It is characterized by somatic mutations or genetic alterations that lead to neoplastic changes and clonal proliferation. Historical treatment paradigms remained largely unchanged throughout the 20th and early 21st centuries, the current treatment of AML stills chemotherapy and stem cell transplantation. Even though advancements in understanding the genetic variances associated with AML have introduced promising new therapeutic options that could potentially improve the outcomes. Tyrosine kinase inhibitors (TKI) such as PKC-412 are one of the recent treatment options that showed successful results. However, in addition to the cost, evidence of resistance to these TKI has been reported. Therefore, searching for alternative, cheaper, available, and effective treatments for AML is vitally needed. This book aimed to be suitable for medical and biomedical students to understand the pathogenesis of AML in molecular aspects and the possible treatment of such malignancies. Therefore, the pathogenesis, therapeutic targets, challenges, and possible therapeutic candidates have been discussed in detail in this book.
Author(s) Details:
Hamid Ali Nagi Al-Jamal,
School
of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin,
Kuala Terengganu, Terengganu 21300, Malaysia.
Belal
Almajali,
Department of Medical Laboratory Sciences, Faculty
of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.
Maysa
Alhawamdeh,
Department of Medical Laboratory Sciences, Faculty
of Allied Medical Sciences, Mutah University, Al-Karak, Jordan.
Hanan
Kamel M. Saad,
School of Biomedicine, Faculty of Health Sciences,
Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu 21300, Malaysia.
Please see the link here: https://stm.bookpi.org/AMLCTCFTC/article/view/12302
No comments:
Post a Comment